EF Hutton Reiterates Buy on Coya Therapeutics, Maintains $28 Price Target
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on Coya Therapeutics (NASDAQ:COYA) and maintained a $28 price target.
July 18, 2023 | 8:08 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
EF Hutton analyst Elemer Piros has reiterated a 'Buy' rating on Coya Therapeutics and maintained a $28 price target.
The reiteration of a 'Buy' rating by EF Hutton, a reputable financial institution, is a positive signal for Coya Therapeutics. The maintained price target of $28 indicates that the analyst believes the stock has potential for growth, which could lead to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100